Publicacións en colaboración con investigadores/as de Hospital Virgen del Camino (15)

2021

  1. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  2. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  3. Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 234-245

  4. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

  5. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

2019

  1. Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial (Cancer Chemotherapy and Pharmacology, (2019), 83, 6, (1175-1181), 10.1007/s00280-019-03820-7)

    Cancer Chemotherapy and Pharmacology

  2. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

  3. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    Cancer Chemotherapy and Pharmacology, Vol. 83, Núm. 6, pp. 1175-1181

  4. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study

    Clinical Breast Cancer, Vol. 19, Núm. 2, pp. 105-112

  5. Predictive model of breast cancer metastasis in axillary non-sentinel lymph nodes. Emergent variables. The MOTTO study, part I

    Revista de Senologia y Patologia Mamaria, Vol. 32, Núm. 4, pp. 127-132

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

2017

  1. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

    Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518

  2. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300